for The force: How to improve ultrasonic plastic welding By www.medicalplasticsnews.com Published On :: Fri, 24 Apr 2020 11:34:58 -0000 Tom Hoover, senior medical business development manager – Americas, assembly technologies, at global technology and manufacturing company, Emerson, explains how ultrasonic plastic welding is improved through improved force control. Full Article
for Scuba mask used to create PPE for healthcare workers By www.medicalplasticsnews.com Published On :: Fri, 24 Apr 2020 15:06:19 -0000 Mack Molding and Southwestern Vermont Health Care (SVHC) have partnered to develop an innovative alternative for Personal Protective Equipment (PPE) for healthcare workers. Full Article
for Choosing a fitting for your medical device: What to consider By www.medicalplasticsnews.com Published On :: Mon, 27 Apr 2020 09:12:22 -0000 Ashley Philipp, marketing director, Injectech, explains the importance of considering barb styles when choosing a fitting for your medical device. Full Article
for ‘Instant’ validated labelling platform available for ventilator manufacturers By www.medicalplasticsnews.com Published On :: Mon, 27 Apr 2020 11:58:18 -0000 Prisym ID, a provider of data-led label and artwork management solutions, is offering instant access to its Prisym 360 SaaS medical devices labelling solution, to support medtech manufacturers’ response to Covid-19. Full Article
for Greenlight Guru announces partnership to simplify global market access for medical device companies By www.medicalplasticsnews.com Published On :: Mon, 27 Apr 2020 14:00:00 -0000 Greenlight Guru, a Medical Device Quality Management Software (MDQMS) platform, has teamed up with Emergo by UL, a consulting firm specialising in global medical device regulatory compliance. Full Article
for Meeting expectations for medical tubing By www.medicalplasticsnews.com Published On :: Tue, 28 Apr 2020 08:50:26 -0000 Olympus highlights two important standards for medical tubing, and explores inspection solutions that can help you meet them. Full Article
for Support terminated for four devices in the Ventilator Challenge By www.medicalplasticsnews.com Published On :: Wed, 29 Apr 2020 09:10:37 -0000 The UK government has announced it will be ending support for four devices in the Ventilator Challenge. Full Article
for AdvaMed asks for additional tariff relief to tackle Covid-19 By www.medicalplasticsnews.com Published On :: Thu, 30 Apr 2020 09:35:03 -0000 The Advanced Medical Association (AdvaMed) has requested the United States Trade Representative (USTR) provides additional tariff exclusions for medical devices, components and supplies coming from China which are necessary to help with Covid-19. Full Article
for Medtech company announces Covid-19 services for ‘at risk’ patients By www.medicalplasticsnews.com Published On :: Thu, 30 Apr 2020 15:55:47 -0000 HealthBeacon, a medication adherence technology company, has launched a new Covid-19 support offering for patients on injectable therapies. Full Article
for Registration is now open for Medtec China 2020 By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 10:16:10 -0000 Exhibitors and attendees can now register for the show which is taking place in Shanghai from 14th to 16th September 2020. Full Article
for Roche receives approval for Covid-19 antibody test By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 11:54:03 -0000 Roche’s antibody test for Covid-19 has been given the CE mark and has been issued Emergency Use Authorisation from the US Food and Drug Administration. Full Article
for Formlabs receives FDA go-ahead to print BiPAP adapters By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 14:00:00 -0000 3D printing company Formlabs has received emergency use authorisation (EUA) from the U.S. Food and Drug Administration (FDA) to print bi-level positive airway pressure (BiPAP) adapters designed by Northwell Health, a New York healthcare provider. Full Article
for University of Glasgow issues plea for acetate sheets to help produce plastic visors By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 14:02:24 -0000 Engineers from the University of Glasgow are responding to the coronavirus pandemic by producing up to 1,000 pieces of Personal Protective Equipment (PPE) each day. Full Article
for Manufacturer forms alliance to cope with the demand for PPE By www.medicalplasticsnews.com Published On :: Tue, 05 May 2020 15:48:04 -0000 Manufacturer and designer, Placon, has introduced the Face Shield Alliance to provide healthcare workers and first responders with adequate Personal Protective Equipment (PPE) during the Covid-19 pandemic. Full Article
for Med-Tech Innovation Expo rescheduled for June 2021 By www.medicalplasticsnews.com Published On :: Wed, 06 May 2020 09:55:25 -0000 Rapid News Group has announced the decision to postpone Med-Tech Innovation Expo, the UK’s flagship event for the medical device industry to 2021. Full Article
for AdvaMed launches platform to help scale the production and distribution of ventilators By www.medicalplasticsnews.com Published On :: Wed, 06 May 2020 13:08:16 -0000 AdvaMed has announced the launch of a new platform, which will attempt to connect ventilator companies with component suppliers to ensure quick scale production and distribution of these devices during the Covid-19 pandemic. Full Article
for Winner announced for Red Dot Design Award By www.medicalplasticsnews.com Published On :: Wed, 06 May 2020 14:12:23 -0000 LoFric Elle – an intermittent catheter with an L-shaped handle – has won the 2020 Red Dot Design Award. Full Article
for Debunking the Myth: ‘Gene Patents’ are not necessary for healthcare innovation. By patentlybiotech.wordpress.com Published On :: Thu, 09 Jun 2011 14:30:39 +0000 Myth: ‘Gene Patents’ are not necessary for health care innovation. Facts: Patents on DNA preparations or sequences are often the first patents upon which a later technology platform or portfolio is built. These patents are often in-licensed from universities by small start-up companies for the purpose of additional R&D, evidencing that the public/non-profit university sector cannot bear […] Full Article Gene Patents DNA patents gene patents gene patents and innovation gene patents and research gene patents are not necessary gene patents are unnecessary gene patents unnecessary healtcare innovation unnecessary gene patents valley of death
for BIO has issued a strong letter of support for the Manager’s Amendment to H.R. 1249, the America Invents Act By patentlybiotech.wordpress.com Published On :: Wed, 15 Jun 2011 17:29:46 +0000 by Stephanie D. Fischer BIO has issued a strong letter of support for the Manager’s Amendment to H.R. 1249, the America Invents Act. The letter is posted on our website and the text is below: “On behalf of the Biotechnology Industry Organization (BIO), I am writing to express our strong support for your Manager’s Amendment […] Full Article Patent Reform Uncategorized America Invents Act BIO fee diversion HR 1249 Managers' Amendment
for Translational Research Forum at BIO International Convention By patentlybiotech.wordpress.com Published On :: Thu, 16 Jun 2011 19:09:54 +0000 BIO is hosting a Translation Research Forum at the BIO International Convention. NIH Director Collins keynotes an event that will explore how private, public and academic sectors can leverage meaningful partnerships, highlight emerging best practices, explore risk-sharing at the clinical research stage, and explore ways to bridge the gap in funding and know-how necessary to take […] Full Article Uncategorized BIO BIO International Convention Francis Collins NIH public pri technology transfer translational research
for Menarini to buy Stemline for up to $677 million By www.pharmatimes.com Published On :: Tue, 05 May 2020 11:17:09 +0100 The move will establish Menarini's presence in the US biopharma market Full Article
for US OK's AZ' Farxiga for heart failure with reduced ejection fraction By www.pharmatimes.com Published On :: Wed, 06 May 2020 12:13:58 +0100 Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction Full Article
for NICE publishes rapid COVID-19 guideline for acute kidney injury By www.pharmatimes.com Published On :: Wed, 06 May 2020 12:21:13 +0100 The guideline is designed to help healthcare professionals who are not kidney specialists to prevent, detect and manage AKI in hospitalised patients with suspected or confirmed COVID-19 Full Article
for Speedy US approval for Novartis' Tabrecta By www.pharmatimes.com Published On :: Wed, 06 May 2020 22:47:33 +0100 The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option Full Article
for E&C Members Hold Bipartisan Teleconference Forum with CDC on Racial Disparities in COVID-19 Health Outcomes By energycommerce.house.gov Published On :: Fri, 01 May 2020 00:00:00 -0400 Members of the Energy and Commerce Committee’s Health and Oversight and Investigations subcommittees today held a bipartisan teleconference forum with Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, M.D., to discuss racial disparities in health outcomes for COVID-19 patients. Health Subcommittee Chairwoman Anna G. Eshoo (D-CA), Health Subcommittee Ranking Member Michael C. Burgess, M.D. (R-TX), Oversight and Investigations Subcommittee Chair Diana DeGette (D-CO) and Oversight and Investigations Subcommittee Ranking Member Brett Guthrie (R-KY) released a joint statement following the call: “Today, bipartisan members of our two subcommittees discussed the deeply troubling racial disparities in health outcomes for COVID-19 patients with CDC’s Principal Deputy Director Schuchat. During the call, members received an update on CDC’s COVID-19 response, current data collection efforts, and reiterated the need for more accurate and timely demographic data. “Congress stands ready to work with the CDC to secure comprehensive demographic data to help us direct resources and support to close this gap in these health outcomes.” ### Full Article
for E&C Committee Members Hold Teleconference Forum with Admiral Giroir on COVID-19 Testing By energycommerce.house.gov Published On :: Mon, 04 May 2020 00:00:00 -0400 Energy and Commerce Committee members held a bipartisan teleconference forum with Admiral Brett P. Giroir, M.D., Assistant Secretary of Health at the Department of Health and Human Services, on the Administration’s COVID-19 testing efforts. Chairman Frank Pallone, Jr. (D-NJ) and Ranking Member Greg Walden (R-OR) released a joint statement following the call: “The Committee continued its discussions with federal health leaders today on the Administration’s ongoing response to the coronavirus pandemic. During the call, members received an update on federal efforts to increase COVID-19 testing and encouraged the Administration to continue working to get more testing supplies to communities in need. “The members asked for more specifics on the testing needs that states have identified, how the federal government is going to increase capacity and what level of testing is necessary to reopen the economy. “Testing is an essential tool in reducing the spread of this horrible virus, and we thank Admiral Giroir for providing the Committee an update today.” ### Full Article
for Pallone, Wyden Slam Trump Admin for Excluding Medicaid Providers from COVID-19 Relief Fund By energycommerce.house.gov Published On :: Wed, 06 May 2020 00:00:00 -0400 House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ) and Senate Finance Committee Ranking Member Ron Wyden (D-OR) called on the Trump administration to address the lack of financial relief for Medicaid providers fighting the COVID-19 pandemic. The two Committee leaders voiced concerns that, to date, roughly $70 billion has been distributed to health care providers under the CARES Act in a way that discriminates against Medicaid-dependent health care providers. “HHS’s continued neglect for the needs of Medicaid-dependent providers struggling to deal with the COVID-19 crisis is unacceptable,” the members wrote. “The country is in the middle of a pandemic. The Medicaid program is a first responder, and the providers it relies on must be treated with equity. At a bare minimum that should include expeditious access to the [provider fund] as intended by Congress.” The Provider Relief Fund that Congress created as a part of the CARES Act, within the Public Health and Social Services Emergency Fund (PHSSEF), was intended to support health care providers including those who participate in Medicare and Medicaid. However, to date only Medicare-enrolled providers have been able to access funds, and these funds are being allocated according to a methodology that rewards providers with high levels of privately-insured individuals while providers supporting the safety net are left waiting. This imbalance discriminates against critical health care providers that primarily service the Medicaid population, such as frontline hospitals, nursing homes and home-based providers, behavioral health providers, maternal health care providers and pediatricians. In the letter, sent to Health and Human Services (HHS) Secretary Alex Azar, Pallone and Wyden called on the Trump administration to describe how much funding will go to Medicaid-dependent providers and the steps it has taken to understand the needs of these providers during the pandemic. The full letter is available here. ### Full Article
for E&C Leaders Announce Committee Teleconference Forum on COVID-19 Testing, Contact Tracing and Surveillance on May 8 By energycommerce.house.gov Published On :: Thu, 07 May 2020 00:00:00 -0400 Energy and Commerce Chairman Frank Pallone, Jr. (D-NJ) and Ranking Member Greg Walden (R-OR) today announced that the Full Committee will hold a teleconference forum on Friday, May 8, at 12 pm (EDT) on COVID-19 testing, contact tracing and surveillance. “Our nation cannot effectively combat this terrible pandemic in the weeks and months ahead without significant testing, contact tracing and surveillance,” Pallone and Walden said. “We look forward to hearing from health experts about what actions they believe are necessary to ensure our communities have the resources they need to fight this pandemic and to confidently reopen their local economies.” During the forum, the Committee will hear from three health experts: Andy Slavitt, former Acting Administrator of the Centers for Medicare & Medicaid Services (CMS) from 2015-2017. Mark McClellan, M.D., Ph.D., former Administrator of CMS from 2004-2006 and former Commissioner of the Food and Drug Administration (FDA) from 2002-2004. Avik Roy,Co-founder and President of the Foundation for Research on Equal Opportunity. This forum is open to the press. Credentialed reporters interested in listening to the forum live should RSVP to cj.young@mail.house.gov by 4 pm today, Thursday, May 7. ### Full Article
for Consumer Protection and Commerce Subcommittee Announces Teleconference Forum with FTC Chairman Simons on May 11 By energycommerce.house.gov Published On :: Thu, 07 May 2020 16:35:29 -0400 Washington, D.C. – Consumer Protection and Commerce Subcommittee Chair Jan Schakowsky (D-IL) and Ranking Member Cathy McMorris Rodgers (R-WA) today announced that the Subcommittee will hold a teleconference forum on Monday, May 11, at 12 p.m. (EDT) with Federal Trade Commission (FTC) Chairman Joseph J. Simons to discuss critical consumer protection issues related to the COVID-19 pandemic. “The COVID-19 pandemic has brought about significant consumer protection concerns that fall under the purview of the FTC, including COVID-19 related scams, price gouging, privacy and data security issues, and more,” Schakowsky and McMorris Rodgers said. “We look forward to hearing from Chairman Simons about the steps FTC is taking to ensure consumers are protected during this pandemic.” This forum is open to the press. Credentialed reporters interested in listening to the forum live should RSVP to Evan.Gilbert@mail.house.gov by 5 pm on Friday, May 8. ### Full Article
for Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses By xconomy.com Published On :: Fri, 01 May 2020 16:31:22 +0000 Lyra Therapeutics, a biotech company developing a new way to treat your persistently runny nose, has raised $56 million in its public markets debut. Late Thursday, Lyra offered 3.5 million shares priced at $16 apiece, which was the high end of its projected $14 to $16 price range. Those shares are expected to begin trading […] Full Article Boston Boston blog main Boston top stories National blog main 480 Biomedical Arsenal Medical Biotech Bob Langer chronic rhinosinusitis clinical trials COVID-19 deals Drug Delivery FDA Genzyme George Whitesides Inflammation investing IPO Keros Therapeutics Life Sciences Lyra Therapeutics Medical Device MIT mometasone furorate North Bridge Venture Partners ORIC Pharmaceuticals Perceptive Advisors Polaris Venture Partners Renaissance Capital startups Zentalis Pharmaceuticals
for FDA Authorizes “Emergency” Use of Gilead’s Remdesivir for Severe COVID-19 By xconomy.com Published On :: Fri, 01 May 2020 21:14:35 +0000 Regulators on Friday afternoon granted emergency authorization for the Gilead Sciences drug remdesivir as a treatment for patients hospitalized with severe COVID-19 infections. The decision makes the antiviral drug, which is delivered via intravenous infusion, the second drug to receive authorization under the FDA’s emergency guidelines for use against the novel coronavirus. The first was […] Full Article National National blog main National top stories Biotech clinical trials FDA Gilead Sciences Life Sciences remdesivir
for Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine By xconomy.com Published On :: Fri, 01 May 2020 22:44:06 +0000 If you’re looking for a Lyme disease vaccine, you can choose from among several—for your dog. A vaccine for humans hasn’t been available for years and few companies have tried to fill that void. Valneva has advanced its Lyme vaccine candidate to mid-stage clinical testing, and the company now has the help of drug giant […] Full Article Europe National blog main New York blog main New York top stories Biotech Centers for Disease Control and Prevention Cholera clinical trials deals Encephalitis FDA GlaxoSmithKline Japanese encephalitis Life Sciences Lyme disease LYMErix Pfizer pneumococcal disease Prevnar SmithKline Beecham Thomas Lingelbach Valneva
for Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M By xconomy.com Published On :: Mon, 04 May 2020 20:45:58 +0000 Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group. Stemline (NASDAQ: STML), a New York-based company, developed the first FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN. The drug, tagraxofusp (Elzonris) […] Full Article Europe blog main National blog main New York New York blog main New York top stories Acquisition Biotech blastic plasmacytoid dendritic cell neoplasm Blood Cancer BPDCN clinical trials Deal Elcin Barker Ergun Ivan Bergstein Life Sciences M&A Menarini Merger Oncology Precision Medicine Stemline Therapeutics transaction
for Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola By xconomy.com Published On :: Tue, 05 May 2020 18:18:24 +0000 Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding. According to financial terms announced Tuesday, Boston-based Alexion (NASDAQ: ALXN) will pay $18 for each outstanding share of Portola (NASDAQ: PTLA). That price is a a nearly 132 percent premium to Monday’s […] Full Article Boston Boston top stories Europe blog main National blog main National top stories San Francisco blog main San Francisco top stories Alexion Pharmaceuticals andexanet alfa Ardhana Sarin Betrixaban Biotech Bristol-myers Squibb clinical trials deals eculizumab FDA Geoffrey Porges Life Sciences Ludwig Hantson paroxysmal nocturnal hemoglobinuria Pfizer Portola Pharmaceuticals Ravulizumab SVB Leerink
for Encouraging Signals for New Cancer Cell Therapy Strategies By xconomy.com Published On :: Wed, 06 May 2020 12:14:46 +0000 Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were presented during the American Association for Cancer Research virtual meeting with encouraging early activity, […] Full Article Boston blog main Boston top stories Boulder/Denver blog main Boulder/Denver top stories Detroit blog main Detroit top stories Europe blog main Europe top stories Indiana blog main Indiana top stories National National blog main New York blog main New York top stories Raleigh-Durham blog main Raleigh-Durham top stories San Diego blog main San Diego top stories San Francisco blog main San Francisco top stories Seattle blog main Seattle top stories Texas blog main Texas top stories Wisconsin blog main Wisconsin top stories Acute Lymphoblastic Leukemia American Association for Cancer Research Biotech cancer Cancer Drugs CAR-T immunotherapy clinical trials FDA Gilead Sciences Gracell Biotechnologies Immunotherapy Iovance Biotherapeutics Kite Pharma Leukemia Life Sciences Melanoma National Cancer Institute Non-Small Cell Lung Cancer Roche University of California at Los Angeles Xinin Wang Yvonne Chen
for AstraZeneca Diabetes Drug Gets FDA OK for Reducing Heart Health Risks By xconomy.com Published On :: Thu, 07 May 2020 00:24:10 +0000 An AstraZeneca diabetes drug that brought in more than $1.5 billion in sales last year has won an FDA nod expanding its use to adults with systolic heart failure, a condition in which the heart struggles to pump with enough force to push enough blood into circulation. The drug, the once-daily pill dapagliflozin (Farxiga), was […] Full Article Europe blog main National National blog main AstraZeneca Biotech Boehringer Ingelheim diabetes Eli Lilly Heart Failure Life Sciences
for Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation By xconomy.com Published On :: Thu, 07 May 2020 01:46:05 +0000 As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday, making it the first therapy cleared by the agency to treat patients whose non-small cell lung cancer (NSCLC) carries a certain genetic mutation. The […] Full Article National National blog main American Cancer Society Biotech cancer Cancer Drugs clinical trials companion diagnostic FDA Foundation Medicine Incyte kinase inhibitor Life Sciences myelofibrosis Novartis ruxolitinib
for PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug By xconomy.com Published On :: Thu, 07 May 2020 07:09:51 +0000 PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study. The deal, announced after the market close Wednesday, will bring South Plainfield, NJ-based PTC (NASDAQ: PTCT) another compound for its pipeline of rare disease drugs. Wellesley, MA-based […] Full Article Boston blog main Boston top stories National blog main New York New York blog main New York top stories Arkin Bio Ventures BioMarin Pharmaceutical Biotech Censa Therapeutics clinical trials Drug Development FDA Life Sciences PTC Therapeutics rare disease
for Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health By xconomy.com Published On :: Thu, 07 May 2020 13:15:48 +0000 Learn how digital tech is accelerating medical breakthroughs by registering your team to attend Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health. While some content focuses on the Boston ecosystem, we’re confident the forum – and virtual networking – will be valuable to a national audience. The May 13, 2020 event will explore the […] Full Article Boston Boston blog main Boston top stories National National blog main National top stories Biotech event Life Science Life Sciences
for Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs By xconomy.com Published On :: Fri, 08 May 2020 13:05:23 +0000 Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did. On Thursday evening, Ayala priced its IPO, which consisted of 3.7 million shares sold for $15 each. That price was the midpoint of the targeted $14 to $16 […] Full Article National National blog main New York blog main New York top stories Acute Lymphoblastic Leukemia Adenoid Cystic Carcinoma Ayala Pharmaceuticals B-cell maturation antigen Biotech Bristol-myers Squibb clinical trials deals Desmoid tumors FDA investing IPO Israel Biotech Fund Life Sciences Novartis Pfizer SpringWorks Therapeutics triple-negative breast cancer
for Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug By xconomy.com Published On :: Sat, 09 May 2020 02:33:40 +0000 Eil Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces a protein involved in cell signaling. […] Full Article Boston blog main Boston top stories Indiana Indiana blog main Indiana top stories National blog main National top stories New York blog main New York top stories Biotech Blueprint Medicines cancer Cancer Drugs clinical trials Eli Lilly FDA Life Sciences medullary thyroid cancer Non-Small Cell Lung Cancer Novartis pralsetinib selpercatinib Thyroid Cancer
for Dr Wajid Hussain appointed new clinical director for digital health at RCP By www.pharmafile.com Published On :: Fri, 02 Aug 2019 11:20:05 +0000 The Royal College of Physicians (RCP) has appointed Dr Wajid Hussain as its new clinical director for digital health. Dr Hussain, a cardiologist and cardiac electrophysicist at the Royal Brompton and Harefield NHS Trust, has a demonstrated interest in IT and health. While he currently represents the views of clinicians on the Trust’s IT committee, Dr Hussain completed a Diploma in Digital Health Leadership at the NHS Digital Academy last year. He is also currently studying for a Master’s in Digital Health leadership at Imperial College London. read more Full Article digital health IT pharma RCP Research and Development Royal College of Physicians Medical Communications Sales and Marketing Business Services Manufacturing and Production
for Former Ergomed CEO appointed as Midatech’s Chief Financial Officer By www.pharmafile.com Published On :: Wed, 11 Sep 2019 13:43:35 +0000 Immunotherapy-focused pharmaceutical company Midatech Pharma has appointed Stephen Stamp as Chief Financial Officer (CFO) with immediate effect. He will be replacing Nick Robbins-Cherry, who has stepped down after five years since joining in 2014. Robbins will nevertheless remain at Midatech until October to facilitate Stamp’s handover in an orderly fashion. Stamp has most recently served as CEO of pharmaceutical firm Ergomed for two years, stepping down in January citing health reasons. Prior to this he was CFO at Ergomed for a year beginning in 2016. read more Full Article ergomed midatech Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
for General Pharmaceutical Council appoints Laura Fraser as director for Scotland By www.pharmafile.com Published On :: Thu, 12 Sep 2019 14:29:57 +0000 The General Pharmaceutical Council has appointed Laura Fraser, former clinical fellow for the Scottish Chief Pharmaceutical Officer as the new Director for Scotland. Fraser has held leadership roles in community pharmacy across Scotland including board member of Community Pharmacy Scotland. She has also worked for the Scottish Government as Clinical Leadership Fellow. Prior to her position as board member she was area and regional manager for nearly nine years. read more Full Article
for Lawsuits as Conduits for Misinformation During COVID-19 By blog.petrieflom.law.harvard.edu Published On :: Thu, 30 Apr 2020 12:00:51 +0000 In addition to tracing the early history of the Missouri and New York suits, we explain how these lawsuits are being used as conduits for misinformation. The post Lawsuits as Conduits for Misinformation During COVID-19 appeared first on Bill of Health. Full Article Featured Health Law Policy International Liability China coronavirus coronavirus pandemic COVID-19 COVID19 eric schmitt foreign sovereignty immunities act fsia Health Law Missouri new york world health organization
for COVID-19 is a Perfect Storm of Hardship for US Immigrant Communities By blog.petrieflom.law.harvard.edu Published On :: Mon, 04 May 2020 12:00:05 +0000 Immigrant communities, along with communities of color and people experiencing existing health inequities, are expected to face disproportionate effects. The post COVID-19 is a Perfect Storm of Hardship for US Immigrant Communities appeared first on Bill of Health. Full Article Featured Health Law Policy Immigration Patient Care Public Health Race Social Determinants of Health coronavirus coronavirus pandemic COVID-19 COVID19 health disparities immigrants immigration and customs enforcement immigration status
for Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson By blog.petrieflom.law.harvard.edu Published On :: Thu, 07 May 2020 14:55:20 +0000 In this video explainer, Christopher Robertson discusses the Right to Try Act and off-label use of pharmaceuticals with Alison Bateman-House. The post Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson appeared first on Bill of Health. Full Article Christopher Robertson FDA Health Law Policy Off-Label Use Pharmaceuticals Public Health alison bateman-house christopher robertson coronavirus coronavirus pandemic COVID-19 COVID19 off-label use Regulation right to try
for For A New Device To Treat Maternal Bleeding, A Young Entrepreneur’s Big Step Was Passing The Torch By www.forbes.com Published On :: Thu, 20 Sep 2018 13:00:00 +0000 This morning, Alydia Health, a tiny Menlo Park, Calif., startup co-founded by a 21-year-old woman, announced that it has secured $10 million in funding to test a medical device to prevent mothers from bleeding to death after childbirth. Full Article byline=Matthew Herper
for Why Former Novartis CEO Joe Jimenez Joined A Microbiome Startup’s Board By www.forbes.com Published On :: Fri, 21 Sep 2018 11:00:00 +0000 uBiome, a San Francisco startup that sells commercial tests that use DNA sequencing to identify what microbes are in a person's stool or, for one test, in the vagina, has raised $83 million from venture capitalists to fund an entrée into drug development. Full Article ticker=NYSE:NVS byline=Matthew Herper
for EPS taps CluePoints for trial management solution By www.outsourcing-pharma.com Published On :: Mon, 27 Apr 2020 15:42:00 +0100 The Japanese pharma development firm will harness risk-based quality management solutions to help sponsors improve trial quality and safety. Full Article Clinical Development